A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease
about
Once-daily LABA/ICS combined inhalers versus inhaled long-acting beta2-agonists for people with chronic obstructive pulmonary disease (COPD)Advances in understanding COPDAn observation of prescription behaviors and adherence to guidelines in patients with COPD: real world data from October 2012 to September 2014.Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome Associated with Risk of Pulmonary Embolism.Metabolic Effects Associated with ICS in Patients with COPD and Comorbid Type 2 Diabetes: A Historical Matched Cohort Study.Relationship between Fractional Exhaled Nitric Oxide Level and Efficacy of Inhaled Corticosteroid in Asthma-COPD Overlap Syndrome Patients with Different Disease SeverityA Belgian survey on the diagnosis of asthma-COPD overlap syndrome.Fixed-Dose combination of the inhaled corticosteroid and long-acting beta2-agonist therapy in adults with persistent asthma.Role of Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Therapy in Chronic Obstructive Pulmonary Disease.The place of inhaled corticosteroids in the treatment of chronic obstructive pulmonary disease: a narrative review.A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease.Inhaled therapies in patients with moderate COPD in clinical practice: current thinking.Individualizing the selection of long-acting bronchodilator therapy for patients with COPD: considerations in primary care.Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD.Optimal Bronchodilation for COPD Patients: Are All Long-Acting β₂-Agonist/Long-Acting Muscarinic Antagonists the Same?
P2860
Q24186189-0CA62A6B-4332-40DD-8A2C-4C2F63A492D1Q28074701-49637480-EF60-45A3-80BB-27825CF063B4Q31100125-7AC4D1DF-1D6B-4E25-8DF3-CF0C842CAC66Q36128095-0C7081DB-8AB8-44A4-BE5E-0E309522C37FQ36141290-A7AB205A-4474-4ED3-9BA4-F2C8F30265A0Q37622312-B4D07A1B-715F-4BD3-BB03-3F9A43857871Q37649862-3B030981-0AB5-46D9-A361-2F69F9ED0CBCQ38707759-506E871D-C856-4E68-BC6E-6DF991BD02C8Q38730318-6BDEC0A5-FC4E-4C55-AD75-2CBDAD1C18E7Q38827675-A724F5A5-FDF5-4411-BA90-5DAFB933E49BQ47138049-261AD419-731A-4516-9B8A-E8B5AF0F2F95Q47661714-558D2B50-5D2D-4272-B450-102D37632049Q47710084-39F84FC6-F671-4BAA-A9AC-D7361AAD3AA0Q55120067-83B3A9F2-1D04-49B2-BA3A-95572933BDA9Q55432750-52295FE5-7921-4651-829A-D922BC2AFFDE
P2860
A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
A re-evaluation of the role of ...... obstructive pulmonary disease
@ast
A re-evaluation of the role of ...... obstructive pulmonary disease
@en
A re-evaluation of the role of ...... obstructive pulmonary disease
@nl
type
label
A re-evaluation of the role of ...... obstructive pulmonary disease
@ast
A re-evaluation of the role of ...... obstructive pulmonary disease
@en
A re-evaluation of the role of ...... obstructive pulmonary disease
@nl
prefLabel
A re-evaluation of the role of ...... obstructive pulmonary disease
@ast
A re-evaluation of the role of ...... obstructive pulmonary disease
@en
A re-evaluation of the role of ...... obstructive pulmonary disease
@nl
P2093
P2860
P921
P3181
P1476
A re-evaluation of the role of ...... obstructive pulmonary disease
@en
P2093
Anthony D'Urzo
David Price
James F Donohue
Peter Kardos
P2860
P304
P3181
P356
10.1517/14656566.2015.1067682
P407
P577
2015-01-01T00:00:00Z